 |
|
Focusing HIV treatment helps control concurrent hepatitis B infection
July 15, 2009WINSTON-SALEM, N.C. - Prolonged use of highly active antiretroviral therapy (HAART) to treat people infected with both HIV and hepatitis B (HBV) helps to better control the hepatitis B infection and could delay or prevent liver complications, according to a new study by researchers at Wake Forest University School of Medicine.
Researchers also found that patients who had higher levels of a common liver enzyme upon beginning treatment for HIV-HBV co-infection were at an increased risk of being diagnosed with cirrhosis within the first few years of follow-up. Cirrhosis is a disease that scars the liver, progressively shutting it down. The enzyme is one released into the bloodstream after liver damage.
"One of the most interesting findings was the confirmation that a simple marker, such as transaminase levels before treatment, is useful in identifying patients at higher risk of developing HBV-related complications in a few years," said lead researcher Marina Núñez, M.D., Ph.D., an assistant professor in the Section on Infectious Diseases, in the Department of Internal Medicine at the School of Medicine.
The study is appears in the May/June issue of HIV Clinical Trials, published today.
HBV is a contagious liver disease, contracted in the same way as HIV - through intravenous drug use, sexual contact or mother-to-newborn transmission. Left untreated, it can lead to fatal liver disease or liver cancer.
HIV increases the activity of HBV, speeds the progression of related liver disease and might decrease the effectiveness of treatments for HBV.
But Núñez and Tsan Lee, a medical student at the School of Medicine, found that prolonged use of highly active antiretroviral therapy, including one or more drugs active against HBV, can lead to clearance of the HBV infection in co-infected patients. HAART is the treatment for HIV infection, consisting of a combination of drugs commonly known as the "cocktail."
For the study, researchers reviewed medical records of patients seen in an adult HIV clinic between 1990 and 2008. They included in the study all patients with positive HIV antibody, hepatitis B and at least three months of follow-up care on record.
Of the 72 patient charts reviewed - primarily black males with a median age of 39 and advanced HIV disease at the time of diagnosis - 64 of the patients received HAART that included drugs effective in treating HBV, for a median duration of one year. The researchers were looking for whether the patients were diagnosed with liver complications such as cirrhosis and liver cancer over the course of treatment, and whether the chronic HBV infection improved.
Analysis showed that receiving HAART combined with HBV treatment for a longer period of time was significantly associated with reduced and, in some cases cleared, chronic HBV infection.
Núñez said these findings "stress the importance of good control of the HIV and HBV infections through maintained compliance with HAART including drugs to treat HBV.
"In HBV-HIV patients with the elevated enzyme levels that signal liver damage, it is even more important to control the HBV infection in an attempt to decrease the risks of complications. Those patients should also be more closely screened for liver complications."
Wake Forest University Baptist Medical Center
The study is appears in the May/June issue of HIV Clinical Trials, published today.
HBV is a contagious liver disease, contracted in the same way as HIV - through intravenous drug use, sexual contact or mother-to-newborn transmission. Left untreated, it can lead to fatal liver disease or liver cancer.
HIV increases the activity of HBV, speeds the progression of related liver disease and might decrease the effectiveness of treatments for HBV.
But Núñez and Tsan Lee, a medical student at the School of Medicine, found that prolonged use of highly active antiretroviral therapy, including one or more drugs active against HBV, can lead to clearance of the HBV infection in co-infected patients. HAART is the treatment for HIV infection, consisting of a combination of drugs commonly known as the "cocktail."
For the study, researchers reviewed medical records of patients seen in an adult HIV clinic between 1990 and 2008. They included in the study all patients with positive HIV antibody, hepatitis B and at least three months of follow-up care on record.
Of the 72 patient charts reviewed - primarily black males with a median age of 39 and advanced HIV disease at the time of diagnosis - 64 of the patients received HAART that included drugs effective in treating HBV, for a median duration of one year. The researchers were looking for whether the patients were diagnosed with liver complications such as cirrhosis and liver cancer over the course of treatment, and whether the chronic HBV infection improved.
Analysis showed that receiving HAART combined with HBV treatment for a longer period of time was significantly associated with reduced and, in some cases cleared, chronic HBV infection.
Núñez said these findings "stress the importance of good control of the HIV and HBV infections through maintained compliance with HAART including drugs to treat HBV.
"In HBV-HIV patients with the elevated enzyme levels that signal liver damage, it is even more important to control the HBV infection in an attempt to decrease the risks of complications. Those patients should also be more closely screened for liver complications."
Wake Forest University Baptist Medical Center
HIV Treatment Current Events and HIV Treatment News RSSGlobal challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
If started early, HIV treatment reduces death rates toward background levels in African countries
Mortality rates of people starting HIV treatment in four African countries approach those of the general population over time, provided that treatment is started before the immune system has been severely damaged, according to research published this week in the open-access journal PLoS Medicine.
Treating HIV earlier to decrease the risk of death
Begin treatment as early as possible: this general common sense rule seems to apply to most diseases except HIV-AIDS, which is only treated once a certain number of immune cells called "CD4+" cells have disappeared.
Waking up dormant HIV
HAART (highly active anti-retroviral therapy) has emerged as an extremely effective HIV treatment that keeps virus levels almost undetectable; however, HAART can never truly eradicate the virus as some HIV always remains dormant in cells.
Study finds major interruptions in antiretroviral therapy after release from prison
The vast majority of HIV-infected Texas prison inmates who receive antiretroviral therapy while incarcerated experience significant interruptions in HIV treatment after their release into the community.
Integrating antiretroviral therapy with TB treatment for co-infections reduces mortality
A South African treatment study conducted by researchers in the Department of Epidemiology at the Mailman School of Public Health shows that mortality among TB-HIV co-infected patients can be reduced by a remarkable 55%, if antiretroviral therapy (ART) is provided with TB treatment at the same time.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death.
Scientists unmask key HIV protein, open door for more powerful AIDS drugs
University of Michigan scientists have provided the most detailed picture yet of a key HIV accessory protein that foils the body's normal immune response.
Researchers Evaluate Cost-Effectiveness of Genetic Screening to Guide Initial HIV Treatment
A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions.
More HIV Treatment Current Events and HIV Treatment News Articles
 |
HIV/AIDS Treatment Drugs (Drugs: the Straight Facts) by Brigid M. Kane (Author) |
 |
Let the Games Begin Directed By: Tom Moore Also With: John Wells (Producer), Michael Crichton (Producer), Lydia Woodward (Producer), Lydia Woodward (Writer) |
 |
AIDS in Africa Also With: MacNeil / Lehrer Productions (Producer) The AIDS crisis in Africa is the subject of this 2001 NewsHour series. Correspondents report on the situation in three countries: Malawi, Botswana and Senegal. Also included is a discussion about the international community's role in combating the epidemic. A warning: segments in the series contain strong images and frank conversations about sexual habits. |
 |
GlyMordica Bitter Melon 450 mg. 60 Capsules by Amazing Herbs - Theramune Bitter melon is one of the few agents which has the potential to bolster a flagging pancreas. Known for it's ability to help with liver problems, Diabetes and HIV also an excellent natural common cold remedy. |
 |
Nutrition and HIV: A New Model for Treatment by Mary Romeyn M.D. (Author) Treating HIV with Nutrition Nutrition and HIV addresses the issues of nutrition and HIV from the perspective of the patient as well as the physician. Everyone who is interested in the problems of--and solutions to--nutritional therapy in HIV owes it to themselves to read this book. This reference book offers a sound nutritional model for sustaining and improving quality of life for HIV positive men and women. It outlines an easy-to-follow program for the prevention and treatment of weight loss--a common problem that if left untreated could lead to serious health decline or even death. |
|
Hiv Aids Treatments Directory by Nam Publications Ltd | |
 |
The Essential HIV Treatment Fact Book by Paul Douglas (Author) The authors of The Essential AIDS Fact Book suggest ways to control the HIV virus while more effective treatments are being developed. Sections include HIV Antibody Testing; Obtaining Treatment; Health Care Strategies; Drugs that Help; Living with HIV; Managing Complications; and more. |
 |
AIDS: And Your Job Also With: National AudioVisual Center (Primary Contributor) |
 |
HIV/AIDS Treatment and Prevention in India: Modeling the Costs and Consequences (Health, Nutrition, and Population) by over Mead (Author), Peter Heywood (Author), Julian Gold (Author), Indrani Gupta (Author), Subhah Hira (Author), Elliot Marseille (Author) How should governments respond to the increasing domestic and international pressures to finance antiretroviral therapy for AIDS patients? Once prohibitively expensive outside rich countries, antiretroviral therapy is now increasingly affordable, especially in India where patent laws and a dynamic pharmaceutical industry have facilitated the production and marketing of some of the best available drug combinations at prices below a dollar a day. This title projects the future implications of three alternative AIDS treatment financing policies for the health burden of AIDS in India and for its overall health expenditures. The Indian government's 2004 treatment initiative contains elements of all three of these options. Written by an interdisciplinary team of AIDS experts, the book... |
 |
HIV Treatment Adherence: Challenging for Social Services (Journal of HIV/AIDS & Social Services) by Lana Sue Ka'opua (Author), Nathan L. Linsk (Author), Lana Sue Ka'opus; Nathan L. Linsk (Editor) Learn the latest social service interventions to promote HIV medication adherence Highly Active Antiretroviral Therapy (HAART) can significantly improve the health outcomes of people living with HIV. Still, benefits rely on the steady adherence to the medication regimen as prescribed. Social Work and HIV: Challenges to Treatment Adherence is a practice-friendly resource with the latest HIV medication client adherence strategies and guidelines. This valuable book provides the tools for assessment of client adherence, and includes approaches and helpful guidelines to develop specialized counseling, social services, and provider training programs. Treatment plans for HIV can be complicated and client adherence can hinge on several... |
| © 2009 BrightSurf.com |